Hemostaseologic and hematologic parameters with aspirin and ticlopidine treatment in patients with cerebrovascular disease: a cross-over study.
No direct comparisons of the effects of ticlopidine and aspirin on platelet aggregability, clotting parameters, and blood count are available in a cross-over study design in humans. We investigated 45 patients with cerebrovascular disease. Twenty-one patients received 300 mg aspirin once daily for 2 weeks and then for 2 more weeks received 250 mg ticlopidine twice daily. In 24 other patients, the scheme was reversed. ADP-induced aggregability was lower during ticlopidine treatment; epinephrine- and collagen-induced aggregabilities were lower with aspirin treatment. Platelet counts were higher during ticlopidine than during aspirin treatment (199.6/ nl with aspirin, 213.0/nl with ticlop dine, p = 0.008), probably reflecting less platelet activation and degradation and a longer platelet survival time induced by ticlopidine treatment.
Droste
D W
DW
Department of Neurology, Medical University Lübeck, Germany.
Siemens
H J
HJ
Sonne
M
M
Kaps
M
M
Wagner
T
T
D000244:Adenosine Diphosphate / Q000494:pharmacology; D000368:Aged; D001241:Aspirin / Q000627:therapeutic use*; D002561:Cerebrovascular Disorders / Q000097:blood / Q000188:drug therapy*; D003094:Collagen / Q000494:pharmacology; D018592:Cross-Over Studies; D004837:Epinephrine / Q000494:pharmacology; D005260:Female; D005340:Fibrinogen / Q000032:analysis / Q000502:physiology; D006487:Hemostasis / Q000187:drug effects; D006801:Humans; D008297:Male; D008875:Middle Aged; D010974:Platelet Aggregation / Q000187:drug effects*; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D010976:Platelet Count / Q000187:drug effects; D011446:Prospective Studies; D013988:Ticlopidine / Q000627:therapeutic use*
D010975:Platelet Aggregation Inhibitors; D000244:Adenosine Diphosphate; D005340:Fibrinogen; D003094:Collagen; D013988:Ticlopidine; D001241:Aspirin; D004837:Epinephrine